BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/21/2021 9:30:52 AM | Browse: 278 | Download: 585
 |
Received |
|
2021-02-03 15:15 |
|
Peer-Review Started |
|
2021-02-03 15:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-31 04:59 |
|
Revised |
|
2021-04-04 12:47 |
|
Second Decision |
|
2021-06-03 08:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-06-03 12:02 |
|
Articles in Press |
|
2021-06-03 12:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-06-13 21:00 |
|
Typeset the Manuscript |
|
2021-07-20 04:42 |
|
Publish the Manuscript Online |
|
2021-07-21 09:30 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Evgeny Imyanitov and Anna Sokolenko |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Higher Education of the Russian Federation |
15-2020-789 |
|
| Corresponding Author |
Evgeny Imyanitov, MD, Professor, Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Pesochny, Leningradskaya str. 68, Saint-Petersburg 197758, Russia. evgeny@imyanitov.spb.ru |
| Key Words |
BRCA1/2 mutations; platinum-based therapy; Poly (ADP-ribose) polymerase inhibitors; drug resistance; Secondary mutations; Intratumoral heterogeneity; Neoadjuvant therapy |
| Core Tip |
BRCA1/2-associated tumors are highly sensitive to platinum compounds and poly (ADP-ribose) polymerase inhibitors, however they eventually acquire resistance to this type of therapy. Restoration of BRCA1/2 function via the second mutation is the most known mechanism of tumor adaptation to the therapeutic pressure. Some studies demonstrate that even chemonaive BRCA1-driven tumors contain a small fraction of BRCA1-proficient cells, suggesting that the loss of the remaining allele of this gene is not the first event in tumor pathogenesis. These pre-existing platinum-resistant cells rapidly repopulate tumor mass during neoadjuvant therapy for ovarian cancer and explain inevitability of the disease relapses after seemingly successful surgical debulking. |
| Publish Date |
2021-07-21 09:30 |
| Citation |
Imyanitov E, Sokolenko A. Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World J Clin Oncol 2021; 12(7): 544-556 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i7/544.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i7.544 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
